Advertisement

ONE-POINT ADVICE: Significance of Aortic Valvuloplasty in the Valve-in-Valve Era

  • Kentaro HayashidaEmail author
Chapter

Abstract

Transcatheter aortic valve implantation (TAVI) was developed as a therapeutic option for those patients who are deemed to be at high risk for surgical aortic valve replacement or inoperable. After the first case was performed by Professor Cribier from the Department of Cardiology, Rouen University in France in 2002 [Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002;106:3006–8], this therapeutic option received the CE Mark in Europe in 2007, and approval from the U.S. FDA was granted to the SAPIEN valve from Edward Lifesciences in 2011 and the CoreValve from Medtronic in 2014. Presently, over 150,000 patients have been treated with this technique worldwide, and it is rapidly improving and prevailing around the world. In October 2013, it finally received insurance reimbursement in Japan. Since then, over 8000 patients have been treated, and the number of facilities approved to perform the procedure is increasing.

References

  1. 1.
    Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002;106:3006–8.CrossRefGoogle Scholar
  2. 2.
    Dvir D, Webb JG, Bleiziffer S, Pasic M, Waksman R, Kodali S, Valve-in-Valve International Data Registry Investigators, et al. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA. 2014;312:162–70.CrossRefGoogle Scholar
  3. 3.
    Webb JG, Mack MJ, White JM, Dvir D, Blanke P, Herrmann HC, et al. Transcatheter aortic valve implantation within degenerated aortic surgical bioprostheses: PARTNER 2 valve-in-valve registry. J Am Coll Cardiol. 2017;69:2253–62.CrossRefGoogle Scholar
  4. 4.
    Deeb GM, Chetcuti SJ, Reardon MJ, Patel HJ, Grossman PM, Schreiber T, et al. 1-year results in patients undergoing transcatheter aortic valve replacement with failed surgical bioprostheses. JACC Cardiovasc Interv. 2017;10:1034–44.CrossRefGoogle Scholar
  5. 5.
    Roy DA, Schaefer U, Guetta V, Hildick-Smith D, Möllmann H, Dumonteil N, et al. Transcatheter aortic valve implantation for pure severe native aortic valve regurgitation. J Am Coll Cardiol. 2013;61:1577–84.CrossRefGoogle Scholar
  6. 6.
    Taramasso M, Pozzoli A, Latib A, La Canna G, Colombo A, Maisano F, et al. New devices for TAVI: technologies and initial clinical experiences. Nat Rev Cardiol. 2014;11:157–67.CrossRefGoogle Scholar
  7. 7.
    Franzone A, Piccolo R, Siontis GC, Lanz J, Stortecky S, Praz F, et al. Transcatheter aortic valve replacement for the treatment of pure native aortic valve regurgitation: a systematic review. JACC Cardiovasc Interv. 2016;9:2308–17.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of CardiologyKeio University School of MedicineTokyoJapan

Personalised recommendations